What are the benefits of cognitive enhancers for Alzheimer's Disease: use of Population Impact Measures
2007

Benefits of Cognitive Enhancers for Alzheimer's Disease

Sample size: 406 publication Evidence: moderate

Author Information

Author(s): Gammanpila Udaya P, Burns Alistair, Heller Richard F, Purandare Nitin

Primary Institution: University of Manchester

Hypothesis

What are the benefits of prescribing cholinesterase inhibitors to slow cognitive decline in Alzheimer's disease compared to treating hypertension?

Conclusion

Using population impact measures, the study shows that cholinesterase inhibitors can significantly prevent cognitive deterioration in Alzheimer's patients.

Supporting Evidence

  • Cholinesterase inhibitors can prevent cognitive deterioration in Alzheimer's patients.
  • Increasing treatment rates can lead to significant improvements in cognitive function.
  • The study provides a new method to assess the population impact of medical interventions.

Takeaway

If we give special medicine to people with Alzheimer's, it can help them think better and not get worse for a while.

Methodology

Literature review and analysis of local and national surveys to calculate the population impact of cholinesterase inhibitors and hypertension treatment.

Potential Biases

Potential overestimation of treatment rates based on local audit data.

Limitations

The study relied on literature review and did not collect new data, which may limit the accuracy of the findings.

Participant Demographics

Population of 217,000 in Oldham, UK, focusing on those aged 65 and above.

Statistical Information

Confidence Interval

95% CI 82.3, 169.1

Digital Object Identifier (DOI)

10.1186/1471-2318-7-25

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication